Event: Apple Watch was officially released at Apple Inc's 2015 spring product conference at 1: 00 a.m. on March 10, Beijing time, accepted the reservation on April 10, and officially went on sale on April 24.
Main points of investment:
Apple watch will build consumers' overall understanding of smart wearable devices, which is good for the ihealth series that has fully docked with Apple Inc's HealthKit platform, and the subsequent sales space will be activated. Apple watch has a "poor health" module, the self-table itself can only collect human movement data and heart rate data, medical and health indicators such as blood pressure, blood sugar, blood oxygen and other indicators still need to be completed by inferior third-party equipment and supporting APP. All their own and third-party data will be converged and shared on the "healthy" APP (that is, the HealthKit platform) on iPhone. Therefore, the hot sale of apple watch will activate the volume of third-party medical wearable devices, the company's independent brand ihealth series as the largest sales of medical products in China, and all the products have completed the docking of non-HealthKit platform, sales are expected to accelerate.
Ihealth series revenue is expected to double in 14 years, and ihealth's share of revenue is expected to increase to 50 per cent in 16 years. Among them, the growth rate of overseas ihealth series has exceeded 50% in 14 years, and the domestic ihealth series has been on sale in July 14, with estimated sales of nearly 20 million. Most of the domestic income comes from the first product that does not cooperate with XIAOMI-Smart sphygmomanometer BP3, and the second cooperative product is expected to be launched in 15 years. As more products are sold on the domestic market, the domestic market is growing rapidly.
In the future, the company's development and application of health big data will be interesting. The connection of intelligent terminals is just the beginning, and the company has completed the collection, storage and preliminary analysis of users' health information. in the follow-up, we hope to use inferior technology to monitor the health status of users after storing, managing and analyzing a large amount of user data. "provide corresponding diagnosis and treatment advice to users in time.
Maintain the "highly recommended" rating. At present, the company's performance is affected by the continuous high cost of market development, R & D and management in the initial stage of promotion, and the short-term performance is not ideal. 14 years because of the investment income of Sun Company, the performance pressure is still great in 15 years. However, considering that the company is a forerunner in the medical industry, the industry is expected to grow explosively, the company's management, R & D and marketing team are excellent, and the company is optimistic about the company's future health big data service and health management business. Raise the target price to 40.32 yuan, corresponding to the market value of 15 billion yuan, it is recommended to continue to pay attention.
Risk hint: the risk of low expectations in the promotion of ihealth series and the risk of intensified competition among domestic enterprises
